Garret M. Hampton

Medicine · Health Sciences

51h-index11.8kcitations205works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(56), PI3K/AKT/mTOR signaling in cancer(42), Cancer Genomics and Diagnostics(39), HER2/EGFR in Cancer Research(28), RNA modifications and cancer(25)

Publications205 total

Data from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
2023Open Access
Data from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2023Open Access
Supplementary Figures 1-7, Methods from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2023Open Access
Data from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2023Open Access
Supplementary Figures 1-7, Methods from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2023Open Access
Data from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 2 from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 2 from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Methods, Figures 1-9, Tables 1-4 from DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
2023Open Access
Data from DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figures 1-2 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
2023Open Access
Supplementary Figure 1 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Figure 4 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Figure 4 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Table 2 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Table 3 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Table 3 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Data from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Henry F. Frierson(15), Lisa M. Sapinoso(13), Lukas C. Amler(13), Mark R. Lackner(11), Christopher A. Moskaluk(8), S Kern(7), Dan Theodorescu(6), Jill M. Spoerke(5), Mark R. Conaway(5), David S. Shames(5), A A Larson(5), Steven M. Powell(4), Ling Huw(4), Carol O’Brien(4), Yulei Wang(4), Webster K. Cavenee(4), Andrew I. Su(3), Peter G. Schultz(3), Andrea Pirzkall(3), Timothy R. Wilson(3)